2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12783
    SCH 50911 hydrochloride 160415-07-6 98%
    SCH 50911 hydrochloride, (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid, a selective, orally-active and competitive γ-Aminobutyric acid B GABA(B) receptor antagonist, binds to GABA(B) receptor with IC50 of 1.1 μM. SCH 50911 hydrochloride antagonizes GABA(B) autoreceptors, increasing the electrically-stimulated 3H overflow with an IC50 of 3 μM.
    SCH 50911 hydrochloride
  • HY-12909
    MK-4409 1207745-58-1 98%
    MK-4409 is a potent oxazole FAAH inhibitor and can be used for the research of inflammatory and neuropathic pain.
    MK-4409
  • HY-12938
    AMG-8718 1215868-94-2 98%
    AMG-8718 is a potent, selective and orally active BACE1 inhibitor with IC50 values of 0.0007, 0.005 µM for BACE1 and BACE2, respectively. AMG-8718 significantly decreases Aβ40 levels in the CSF and brain.
    AMG-8718
  • HY-13051
    SB-773812 630407-66-8 98%
    SB-773812 is a selective 5-HT6 receptor antagonist. SB-773812 is promising for research of central nervous system disorders.
    SB-773812
  • HY-13052
    SB-737050A 583045-76-5 98%
    SB-737050A is a potent 5-HT6 antagonist to prevent relapse into addiction.
    SB-737050A
  • HY-13486
    TAU-IN-1 1383373-65-6 98%
    TAU-IN-1 (compound 051) is a TAU protein inhibitor with an EC50 value of 325 nM. TAU-IN-1 can be used in the study of neurodegenerative diseases.
    TAU-IN-1
  • HY-13597
    CJ-15161 204970-97-8 98%
    CJ-15161 is a κ-opioid receptor agonist. CJ-15161 can be used to study physiological functions such as pain relief and emotional regulation.
    CJ-15161
  • HY-13709
    Gantacurium chloride 213998-46-0 98%
    Gantacurium is an ultrashort-acting, nondepolarizing neuromuscular blocking agent that is degraded by nonenzymatic binding to L-cysteine under physiological conditions. Gantacurium causes a decrease in mean arterial pressure and an increase in heart rate.
    Gantacurium chloride
  • HY-13710
    Dimethindene 5636-83-9 98.94%
    Dimethindene is a potent, selective histamine H1 antagonist. Dimethindene impairs cutaneous wound healing (WH). Dimethindene can block K+ currents.
    Dimethindene
  • HY-13736
    Quinagolide 87056-78-8 98%
    Quinagolide (CV205-502) is a non-ergot dopamine D(2) receptor agonist that promotes dopamine activity. Quinagolide has shown effectiveness in modulating endocrine function, particularly in inhibiting disorders associated with dopamine deficiency. Quinagolide is used to suppress hyperprolactinemia and corresponding clinical symptoms, showing good efficacy. Quinagolide's biological activity enables its use as an important research compound in drug isolation and analysis.
    Quinagolide
  • HY-14124
    MK-5757 919482-44-3 98%
    MK-5757 is a Nociceptin/Orphanin FQ Peptide Receptor antagonist. ORL1 antagonist 3 can improve cerebral blood flow disorders and ischemic damage, and alleviate abnormal neurological symptoms. ORL1 antagonist 3can be used for the research of neurological disease, such as traumatic brain injury.
    MK-5757
  • HY-14129
    CP 316311 175139-41-0 98%
    CP 316311 is a potent and selective CRF1 receptor antagonist with an IC50 value of 6.8 nM.
    CP 316311
  • HY-14132
    BMS-665053 1173435-64-7 98%
    BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM).
    BMS-665053
  • HY-14148
    Renzapride hydrochloride 109872-41-5 98%
    Renzapride hydrochloride is a benzamide that inhibits irritable bowel syndrome and has antagonistic activity at 5-HT(3) receptors and agonistic activity at 5-HT(4) receptors. Renzapride hydrochloride also exhibits antagonistic activity at 5-HT(2B) receptors and has a certain affinity for 5-HT(2A) and 5-HT(2C) receptors.
    Renzapride hydrochloride
  • HY-14154
    THRX-194556 886579-13-1 98%
    THRX-194556 is a 5-HT4 receptor agonist. THRX-194556 can be used to study gastrointestinal functional disorders and Alzheimer’s disease.
    THRX-194556
  • HY-14160
    CB2 receptor agonist 7 871819-90-8 98%
    CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability.
    CB2 receptor agonist 7
  • HY-14202
    Lazabemide hydrochloride 103878-83-7 98%
    Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide  inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease.
    Lazabemide hydrochloride
  • HY-14222
    UMB24 1033-69-8 98%
    UMB24 is a potent antagonist of σ2 receptor, with Ki values of 170 nM anf 322 nM for σ2 receptor and σ1 receptor, respectively. UMB24 attenuats cocaine-induced convulsions and locomotor activity, but not lethality.
    UMB24
  • HY-14223
    SM-21 155058-71-2 98%
    SM-21 is a derivative of R-(+)-hyoscyamine with potent antinociceptive and cognitive enhancing activities. SM-21 works by affecting the release of acetylcholine.
    SM-21
  • HY-14225
    BMS-764459 1188407-45-5 98%
    BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer.
    BMS-764459
Cat. No. Product Name / Synonyms Application Reactivity